27th week of 2014 patent applcation highlights part 55 |
Patent application number | Title | Published |
20140187442 | FLOW CYTOMETRY FOR HIGH THROUGHPUT SCREENING - The present invention, provides a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles. The present invention also provides a flow cytometry method employing such an apparatus. | 2014-07-03 |
20140187443 | ANTIBACTERIAL AND PLASMID ELIMINATION AGENTS - Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including | 2014-07-03 |
20140187444 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING O-GLYCOSYLATION - The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention is also useful for identifying therapeutic compounds to treat de-glycosylation-associated disorders such as ischemic damage and traumatic injury. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins and also relates in part to compounds to treat glycosylation-associated diseases and disorders. | 2014-07-03 |
20140187445 | ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS - The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies. | 2014-07-03 |
20140187446 | AFFINITY-BASED DETECTION OF BIOLOGICAL TARGETS - A method of biochemical identification by: providing a plurality of capture species bound to one or more substrates and suspected of having one or more biological targets affinity bound to at least one capture species; detecting which capture species contain bound biological targets to generate a binding pattern; and identifying the biological target based on the binding pattern. The capture species are independently selected from the group consisting of antimicrobial peptides, cytotoxic peptides, antibiotics, and combinations thereof. A device having the capture species bound to the substrates. At least two of the capture species are capable of multi-specific binding to one or more biological targets and may have overlapping but not identical affinity properties. | 2014-07-03 |
20140187447 | Ligation Enhancement - Compositions and methods are provided for enhancing enzymatic ligation between nucleic acid fragments that relies on one or more small molecule enhancers having a size of less than 1000 daltons. For example, enhancement of ligation efficiencies are observed for double-stranded nucleic acid fragments that are blunt-ended, have a single nucleotide overhang at the ligation end, or have staggered ends compared to ligation under similar conditions in the absence of the one or more small molecule ligation enhancer. The use of small molecule enhancers for ligating nucleic acids results in an increased number of transformed host cells after transformation with the ligated molecules. This enhancement can be observed with chemically transformed host cells and with host cells transformed by electroporation. | 2014-07-03 |
20140187448 | Radio Frequency Identifiers for Use in Biological Science - Provided herein are biological research methods, kits, and products that utilize radio frequency identifier technology. | 2014-07-03 |
20140187449 | FUNCTIONALIZED SILICATE NANOPARTICLE COMPOSITION, REMOVING AND EXFOLIATING ASPHALTENES WITH SAME - Removing an asphaltene particle from a substrate includes contacting a silicate nanoparticle with a chemical group to form a functionalized silicate nanoparticle, the chemical group includes a first portion; and a second portion comprising an aromatic moiety, the first portion being bonded to the silicate nanoparticle; contacting the asphaltene particle with the functionalized silicate nanoparticle, the asphaltene particle being disposed on the substrate; interposing the functionalized silicate nanoparticle between the asphaltene particle and the substrate; and separating the asphaltene particle from the substrate with the functionalized silicate nanoparticle to remove the asphaltene particle. A composition includes a functionalized silicate nanoparticle comprising a reaction product of a silicate nanoparticle and an aromatic compound; and a fluid. The aromatic compound includes a chemical group that includes a first portion, the first portion being directly bonded to the silicate nanoparticle in the functionalized silicate nanoparticle; and a second portion including an aromatic moiety. | 2014-07-03 |
20140187450 | Internal Breaker for Fluid Loss Control Pills and Method - A method of treating a subterranean formation. The method may include providing a fluid-loss control pill that comprises an aqueous base fluid, a gelling agent, and an internal breaker that is selected from the group consisting of inorganic delayed acids or inorganic salts. The method can include introducing the fluid-loss control pill into a subterranean formation, allowing the internal breaker to reduce the viscosity of the pill after a delay period, and allowing the fluid-loss control pill to break. | 2014-07-03 |
20140187451 | Producing Nanostructure of Polymeric Core-Shell to Intelligent Control solubility of Hidrophilic Polymer during Polymer Flooding Process - Hydrophilic polymer particles have been obtained using polyacrylamide, xanthane, maleic anhydride polymers, allylamine, ethyleneimine, and oxazoline as core polymers. Then, hydrophobic polymers shells have been produced on the core-side using styrene, styrene copolymers, polyvinyl state, polysolfune, polymethyl methacrylate, and polycyclohxyl methacrylate by in-situ polymerization of monomer as method one and inverse emulsion process as method two. These particles can release hydrophilic polymers at oil-water interface at the reservoir temperature where the water flooding should have the maximum viscosity. So, active materials cause to decrease the mobility ratio of water to oil in the reservoirs and on the other hand, plug the swept porosities and prevent to act the water fingering process. | 2014-07-03 |
20140187452 | Treated Geothermal Brine Compositions With Reduced Concentrations of Silica, Iron and Manganese - This invention relates to treated geothermal brine compositions containing reduced concentrations of iron, silica, and manganese compared to the untreated brines. Exemplary compositions contain a concentration of manganese less than 10 mg/kg, a concentration of silica ranging from less than 10 mg/kg, and a concentration of iron less than 10 mg/kg, and the treated geothermal brine is derived from a Salton Sea geothermal reservoir. | 2014-07-03 |
20140187453 | ULTRA-LOW SAPS LUBRICANTS FOR INTERNAL COMBUSTION ENGINES - Disclosed is an ultra-low SAPS lubricating oil composition comprising:
| 2014-07-03 |
20140187454 | COMPOSITIONS - Additive composition for use in a fuel or lubricant formulation, comprising an active substance in an inclusion complex with a modified cyclodextrin of formula (I): | 2014-07-03 |
20140187455 | ULTRA-LOW SAPS LUBRICANTS FOR INTERNAL COMBUSTION ENGINES - Disclosed is an ultra-low SAPS lubricating oil composition comprising:
| 2014-07-03 |
20140187456 | METHOD OF PREPARING A LUBRICANT COMPOSITION - A method of preparing a lubricant composition comprising at least one base oil component, at least one first additive component and at least one second additive component which method comprises:
| 2014-07-03 |
20140187457 | LUBRICATING COMPOSITIONS HAVING IMPROVED SHEAR STABILITY - A lubricating composition with improved shear stability having a kinematic viscosity (Kv | 2014-07-03 |
20140187458 | Lubricating Composition With Improved TBN Retention - The invention provides a lubricating composition containing a diarylamine, an aminobenzene and an oil of lubricating viscosity. The invention further relates to the use of the lubricating composition in an internal combustion engine. The invention further relates to the use of the lubricating composition to improve TBN retention. | 2014-07-03 |
20140187459 | DIALKYL ETHER, AND LUBRICANT BASE OIL AND LUBRICATING OIL COMPOSITION CONTAINING THE SAME - The invention provides a dialkyl ether represented by the following formula (1): | 2014-07-03 |
20140187460 | REMOVAL OF MASKING MATERIAL - Methods for removing a masking material, for example, a photoresist, and electronic devices formed by removing a masking material are presented. For example, a method for removing a masking material includes contacting the masking material with a solution comprising cerium. The cerium may be comprised in a salt. The salt may be cerium ammonium nitrate. | 2014-07-03 |
20140187461 | POLYMERIC AGENTS THAT IMPROVE PRIMARY WASHING EFFICIENCY - The primary washing power of washing and cleaning agents was to be improved, in particular with respect to oil- and/or fat-containing stains. This was achieved substantially by the incorporation of polymers that derive from N,N-dimethylacrylamide. | 2014-07-03 |
20140187462 | POLYMERIC AGENTS THAT IMPROVE PRIMARY WASHING EFFICIENCY - The primary washing power of washing and cleaning agents was to be improved, in particular with respect to oil- and/or fat-containing stains. This was achieved substantially by the incorporation of polymers having an aggregation parameter X | 2014-07-03 |
20140187463 | NOVEL WHITENING AGENTS FOR CELLULOSIC SUBSTRATES - This invention relates to novel whitening agents for cellulosic substrates. The whitening agents are comprised of at least two components: at least one chromophore component and at least one polymeric component. Suitable chromophore components generally fluoresce blue, red, violet, or purple color when exposed to ultraviolet light, or they may absorb light to reflect these same shades. The whitening agents are further characterized by having a dispersion component value of the Hansen Solubility Parameter of less than or equal to about 17 MPa | 2014-07-03 |
20140187464 | CONTROLLING A RELEASE OF A CLEANING AGENT WITH SILICA PARTICLES - Compositions and apparatus are provided for controlling a release of a cleaning agent with silica particles. Silica particles disposed within the gel composition and are configured to at least partially dissolve in an alkaline environment. Further, an active cleaning agent sorbed by the silica particles is configured to be released from the silica particles upon partial dissolution of the silica particles. | 2014-07-03 |
20140187465 | WASHING AND CLEANING AGENT HAVING IMPROVED PERFORMANCE - The present invention relates to the use of polyamidohydroxamates in washing and cleaning agents to improve cleaning performance, in particular with regard to stains containing polymerizable dyes. | 2014-07-03 |
20140187466 | LAUNDRY DETERGENTS AND METHODS FOR MAKING LAUNDRY DETERGENTS CONTAINING METHYL ESTER ETHOXYLATES - Laundry detergents, aqueous liquid laundry detergents, and methods for making laundry detergents are provided herein. In one embodiment, a laundry detergent includes an anionic surfactant and a nonionic surfactant including a methyl ester ethoxylate stable in an alkaline environment. | 2014-07-03 |
20140187467 | DIOXIRANE COMPOUNDS AND USES THEREOF - A dioxirane-containing compound has a first substituent that is an alkyl, polyalkoxy, aryl, heteroaryl, or heterocyclyl group, and a second substituent that is an electron withdrawing group, and where the first and second substituents can optionally join to form a cycloalkyl or heterocyclyl group. The dioxirane-containing compound can be used as an oxidant, surfactant, and/or an ionic liquid. | 2014-07-03 |
20140187468 | Compositions and Methods Comprising a Lipolytic Enzyme Variant - The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having one or more modifications as compared to a parent lipolytic enzyme having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention. | 2014-07-03 |
20140187469 | AQUEOUS FORMULATION FOR DISPENSING AS A SPRAY POLYMERIC MICROCAPSULES CONTAINING AT LEAST ONE ACTIVE INGREDIENT - An aqueous formulation for dispensing as a spray polymeric microcapsules containing at least one active ingredient, the aqueous formulation comprising: (i) water; (ii) polymeric microcapsules having an oil-soluble core containing the at least one active ingredient; (iii) a cross linked acrylic acid co-polymer; (iv) a neutralising amine for activating the cross linked acrylic acid copolymer to form a gel suspension for the polymeric microcapsules whereby the polymeric microcapsules are suspended in the water; (v) a chelant for protecting the aqueous formulation against destabilisation by excessive metal ions; and (vi) an inhibitor for inhibiting bacterial growth in the water. | 2014-07-03 |
20140187470 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases. | 2014-07-03 |
20140187471 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula | 2014-07-03 |
20140187472 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula | 2014-07-03 |
20140187473 | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members - The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent. | 2014-07-03 |
20140187474 | THERAPEUTIC USE OF MUCIN GLYCANS - A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described. | 2014-07-03 |
20140187475 | Lantibiotic Compositions and Methods For Preventing or Treating Mastitis - A composition suitable for application to the skin comprising at least one lantibiotic, an acidic external phase aqueous solution, at least one pharmaceutically acceptable internal phase carrier material, and a combination thereof. A method for preventing or treating mastitis, comprising administering to a human in need of such treatment a topical composition comprising a therapeutically-effective amount of at least one lantibiotic, an acidic aqueous solution, and at least one pharmaceutically acceptable carrier material. | 2014-07-03 |
20140187476 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION - This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections. | 2014-07-03 |
20140187477 | INHIBITORS OF VIRAL INTEGRASE AND METHODS OF USE - Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors. | 2014-07-03 |
20140187478 | PEPTIDE TOXIN FORMULATION - Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation. | 2014-07-03 |
20140187479 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM - Novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. Compositions, particularly pharmaceutical compositions, as well as methods to treat excess weight, obesity and diseases associated with an abnormal fat metabolism. | 2014-07-03 |
20140187480 | METABOLIC IMPRINTING EFFECTS OF SPECIFICALLY DESIGNED LIPID COMPONENT - The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life. | 2014-07-03 |
20140187481 | Transdermal Pharmaceutical Delivery Composition - A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent. | 2014-07-03 |
20140187482 | INSULIN PREPARATION - The present invention relates to an insulin preparation that contains a self-assembling peptide. More specifically, the present invention is an insulin preparation containing a self-assembling peptide of SEQ ID NO:1. | 2014-07-03 |
20140187483 | GLP-1 AND METHODS FOR TREATING DIABETES - The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday”. Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin. | 2014-07-03 |
20140187484 | NA/K-ATPASE-DERIVED PEPTIDE SRC INHIBITORS AND OUABAIN ANTAGONISTS AND USES THEREOF - A novel Src inhibitor that targets the Na/K-ATPase/Src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed. | 2014-07-03 |
20140187485 | NOVEL RECEPTOR NUCLEIC ACIDS AND POLYPEPTIDES - Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided. | 2014-07-03 |
20140187486 | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease - The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent. | 2014-07-03 |
20140187487 | AFFINITY-BASED CONTROLLED RELEASE SYSTEM - Prolonged or extended release of bioactive protein is achieved using an affinity-based approach which exploits the specific binding of Src homology 3 (SH3) domain with short proline-rich peptides. Specifically, methylcellulose was modified with SH3-binding peptides (MC-peptide) with either a weak affinity or strong affinity for SH3. Controlled release of chondroitinase ABC (ChABC) is also described. | 2014-07-03 |
20140187488 | METHODS FOR MAINTAINING PEGYLATION OF POLYPEPTIDES - Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage. | 2014-07-03 |
20140187489 | MUCOSAL DELIVERY OF DRUGS - The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C | 2014-07-03 |
20140187490 | Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome - A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010. | 2014-07-03 |
20140187491 | RELAXIN FUSION POLYPEPTIDES AND USES THEREOF - The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides. | 2014-07-03 |
20140187492 | Single Component Fibrin Hemostat - ClotGel is a single-component hemostatic agent designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its crosslinking technology generates an adhesive stable fibrin clot using a single component (fibrin II) required for hemostasis. The agent is a mixture of lyophilized polymerized fibrin II and fibrin II monomer which is polymerized and stabilized when in contact with the blood. The attachment properties of the gel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed within 1 minute of application. | 2014-07-03 |
20140187493 | PEPTIDE COMPOSITION FOR CANCER TREATMENT BY INHIBITING TRPV6 CALCIUM CHANNEL ACTIVITY - The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer. | 2014-07-03 |
20140187494 | INHIBITION OF INFLAMMATION USING ANTAGONISTS OF MUC1 - The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling. | 2014-07-03 |
20140187495 | METHODS FOR TREATING GLIOBLASTOMA - Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent. | 2014-07-03 |
20140187496 | SGEF CONTROLS MACULAR, CORPUS CALLOSUM AND HIPPOCAMPAL FUNCTION AND DEVELOPMENT, LIVER HOMEOSTASIS, FUNCTIONS OF THE IMMUNE SYSTEM, FEVER RESPONSE ATHEROSCLEROSIS AND TUMOROGENIC CELL GROWTH - The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene or altered levels of the SGEF mRNA or protein. A change of at least about 20% in the level of expression visa-vie a normal individual indicates an SGEF anomaly. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers. | 2014-07-03 |
20140187497 | Ocular Drug Delivery Devices - A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders. | 2014-07-03 |
20140187498 | PREDICTING AND TREATING DIABETIC COMPLICATIONS - Compositions and methods for diagnosing, predicting risk of, and/or treating diabetic retinopathy and/or diabetic nephropathy. | 2014-07-03 |
20140187499 | SUBSTITUTED ANIONIC COMPOUNDS CONSISTING OF A BACKBONE MADE UP OF A DISCRETE NUMBER OF SACCHARIDE UNITS - The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1≦u≦8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic acids, N-acetylhexosamines in cyclic form or in open reduced form, which are randomly substituted. It also relates to the process for the preparation thereof and to the pharmaceutical compositions comprising same. | 2014-07-03 |
20140187500 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES - The present application provides, among other things, compounds, compositions and methods for treating various diseases including cancer. | 2014-07-03 |
20140187501 | Targeted Conjugates Encapsulated in Particles and Formulations Thereof - Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases. | 2014-07-03 |
20140187502 | PEPTIDE LINKERS FOR POLYPEPTIDE COMPOSITIONS AND METHODS FOR USING SAME - Disclosed herein are novel peptide linkers and polypeptide compositions comprising the linkers (e.g., chimeric polypeptides) and methods of using the polypeptide compositions. The compositions and methods are particularly useful for targeting/delivering a polypeptide or protein of interest (e.g., a therapeutic polypeptide) to a cell, tissue or organ of interest in order to treat various diseases or disorders (e.g., lysosomal storage disorders). | 2014-07-03 |
20140187503 | DIAGNOSTIC METHOD - It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis. | 2014-07-03 |
20140187504 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS - The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis. | 2014-07-03 |
20140187505 | Cardiac Glycosides to Treat Cystic Fibrosis and Other IL-8 Dependent Disorders - Disclosed is the use of a cardiac glycoside to decrease or inhibit the secretion of proinflammatory mediators in the treatment of disease conditions characterized by elevated levels of the proinflammatory mediator. The cardiac glycoside is administered to a mammalian subject in need of such treatment, and dosage is adjusted to the mass of the recipient and the need of the recipient to reduce or inhibit the level of the proinflammatory mediator. The proinflammatory mediators suppressed by the invention include IL-8, IL-6, TNFalpha, ICAM-1, IFNgamma, IL-1-beta, MCP-1, MIP-2, and/or epithelial-mesenchymal-transition (EMT). The cardiac glycoside, digitoxin or oleandrin, can be formulated for administration by injection or as an aerosol administered to the respiratory tract or by being ingested, or as nose drops or nasal spray. According to one use, the digitoxin controls microRNA expression in castration-resistant prostate cancer. The microRNA suppresses IL-8 and IL-6 expression in these cells. | 2014-07-03 |
20140187506 | Inhibitors of Advanced Glycation End Products - The present invention provides compounds of the formula, | 2014-07-03 |
20140187507 | TREATMENT OF PARKINSONS DISEASE WITH GLYCOLIPIDS - This invention provides compounds, compositions, and methods for treating Parkinson's disease. In particular, there is provided GM1 ganglioside analogs that are capable of penetrating the blood brain barrier and entering the cytoplasm of neurons. Endogenous GM1 interacts with the with GFRα1/RET, the GDNF receptor complex involved in GDNF signaling which is essential for neuron survival. In neurons that are deficient in endogenous GM1, the GM1 analog compounds of the invention are capable of restoring GDNF signaling thereby preventing neuron cell death. | 2014-07-03 |
20140187508 | SYNERGISTIC FUNGICIDAL COMPOSITIONS - A synergistic fungicidal mixture contains a fungicidally effective amount of a compound of Formula I and at least one fungicide selected from the group consisting of tricyclazole, azoxystrobin, carpropamid, probenazole, kasugamycin, and boscalid. | 2014-07-03 |
20140187509 | USE OF S-ADENOSYLMETHIONINE, VITAMIN E, AND VITAMIN C FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DYSFUNCTION - The present invention provides a method of preventing or treating cardiovascular dysfunction by administering a therapeutically effective amount of (a) one or more of (i) S-adenosylmethionine or a derivative or pharmaceutically acceptable salt thereof and (ii) N-acetylcysteine or a derivative or pharmaceutically acceptable salt thereof; (b) vitamin E or a derivative or pharmaceutically acceptable salt thereof; and (c) vitamin C or a derivative or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. | 2014-07-03 |
20140187510 | MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed. | 2014-07-03 |
20140187511 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 2014-07-03 |
20140187512 | USE OF LACTULOSE IN THE TREATMENT OF AUTISM - A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity. | 2014-07-03 |
20140187513 | METHOD OF IMPROVING SKILLS WITH A COMPOSITION COMPRISING NON-DIGESTIBLE SACCHARIDE - The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora. | 2014-07-03 |
20140187514 | Use Of Iron(III) Complex Compounds - The present invention relates to novel therapeutic uses of iron(III) complex compounds with carbohydrates or derivatives thereof, in the preparation of a medicament for improving immune defense and/or brain performance. | 2014-07-03 |
20140187515 | METHOD FOR REDUCING DAMAGE BY HARMFUL ORGANISMS IN CORN CULTIVATION - Provided is a method for reducing damage by harmful organisms in corn cultivation. Damage by harmful organisms in corn cultivation can be reduced by carrying out the steps of: A) making a furrow in a cultivated land; B) seeding corn into the furrow formed in the foregoing step; C) applying to the furrow one or more selected from the below-mentioned compound group (I) and chlorpyrifos; and D) closing the furrow. compound group (I): group consisting of clothianidin, thiamethoxam, imidacloprid and thiacloprid. | 2014-07-03 |
20140187516 | DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR - S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile. | 2014-07-03 |
20140187517 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 2014-07-03 |
20140187518 | ANTI-ITCH SCALP TREATMENT COMPOSITIONS AND COMBINATIONS - Provided herein are sulfate free and/or sodium chloride free scalp treatment compositions comprising corticosteroid, combinations containing these compositions, kits and methods, particularly for treating and/or preventing itchy scalp. | 2014-07-03 |
20140187519 | BIOMARKERS FOR PREDICTING MAJOR ADVERSE EVENTS - Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C. | 2014-07-03 |
20140187520 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF VITAMIN D RECEPTOR AGONIST AND PROCESS FOR PREPARATION THEREOF - The present invention relates to a stable pharmaceutical composition for intravenous administration comprising a Vitamin D receptor agonist, particularly paricalcitol, and a process of preparation thereof. | 2014-07-03 |
20140187521 | AMELIORATION OF INTESTINAL FIBROSIS AND TREATMENT OF CROHN'S DISEASE - Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn's disease involve administering a therapeutic amount of CARD-024 or related compound. | 2014-07-03 |
20140187522 | Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism - Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D | 2014-07-03 |
20140187523 | TOPICAL CORTICOSTEROIDS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2014-07-03 |
20140187524 | Treatment of Depressive Disorders - Pregn-4-en-20-yn-3β-one is useful in the treatment of depressive disorders by nasal administration. | 2014-07-03 |
20140187525 | METHOD FOR TREATING UTERINE FIBROIDS - The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids. | 2014-07-03 |
20140187526 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RESPONSIVE TO PROTEASOME INHIBITION - The invention disclosed herein generally relates to methods and compositions for inhibiting proteasome activity comprising a syrbactin compound having the structure of Formula I or II: | 2014-07-03 |
20140187527 | Macrocyclic Compounds And Metal Complexes For Bioimaging And Biomedical Applications - The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear medicines and other biomedical applications in the therapeutics or diagnostics. | 2014-07-03 |
20140187528 | TAZOBACTAM ARGININE ANTIBIOTIC COMPOSITIONS - This disclosure provides compositions comprising a beta-lactam compound and crystalline tazobactam arginine, and related methods and uses of these compositions. | 2014-07-03 |
20140187529 | AMINOPYRAZINE COMPOUNDS - A compound of formula (I): | 2014-07-03 |
20140187530 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases - The present invention provides a compound of Formula I or Formula II: | 2014-07-03 |
20140187531 | APOPTOSIS PROMOTERS - Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. | 2014-07-03 |
20140187532 | 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS - 4-(azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: | 2014-07-03 |
20140187533 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL - The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) or Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions. Formula (I) | 2014-07-03 |
20140187534 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF - A compound of the following general formula [I]: | 2014-07-03 |
20140187535 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The disclosure relates to Substituted Benzimidazole-Type Piperidine Compounds of Formula (I): | 2014-07-03 |
20140187536 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS - Methods for reducing toxicity or side effects caused by administration of a rycal compound for repairing ryanodine receptor channel leaks when treating a disorder in a subject caused by such leaks. These methods are based upon the selection for administration of those rycal compounds having properties including an EC | 2014-07-03 |
20140187537 | METHODS OF PREDICTING OUTCOMES OF CHEMOTHERAPY TREATMENTS AND ALTERNATIVE THERAPIES - This disclosure relates to diagnostic and therapeutic methods and systems related thereto. In certain embodiments, the disclosure contemplates methods of improving chemotherapy treatments by administering chemotherapy agents, analyzing CHFR gene expression, methylation, or both, and determining an appropriate therapeutic strategy. Analysis of data herein revealed that reduced CHFR expression levels was a predictor of improved overall survival of subject with non-small cell lung cancer. | 2014-07-03 |
20140187538 | LORCASERIN HYDROCHLORIDE - The present invention relates to amorphous lorcaserin hydrochloride; amorphous solid dispersion comprising lorcaserin hydrochloride and one or more pharmaceutically acceptable carries; processes for preparation thereof; pharmaceutical compositions comprising amorphous lorcaserin hydrochloride and one or more pharmaceutically acceptable carries. | 2014-07-03 |
20140187539 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS - Heteroaryloxy-substituted benzoic acid amides of general formula I | 2014-07-03 |
20140187540 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 2014-07-03 |
20140187541 | COMPOSITION AND METHOD FOR CONTROLLING HARMFUL ARTHROPODS - The present invention provides a composition for controlling harmful arthropods having an excellent control efficacy on harmful arthropods. A composition for controlling harmful arthropods comprising a carboxylic acid compound represented by a formula (I); wherein each of symbols are the same as defined in the Description; or salts thereof and at least one kind of neonicotinoid compounds selected from the group (A) consisting of imidacloprid, clothianidin, thiamethoxiam, dinotefuran, acetamiprid, thiacloprid and nitenpyram, shows an excellent controlling efficacy on harmful arthropods. | 2014-07-03 |